DFS, OS Benefit Maintained With Adjuvant Atezolizumab vs BSC in Stage II/IIIA NSCLC

Long-term DFS and OS outcomes with adjuvant atezolizumab in stage II to IIIA NSCLC were consistent with prior data from the IMpower010 trial.

Related Keywords

, Winston Chen , Heathera Wakelee , Stanford Cancer Institute , Phyllis Huang Professor , Stanford Medicine , Medical Oncology ,